Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.
Conditions
Interventions
IPN60300
Locations
12
United States
Yale Cancer Center-Yale University
New Haven, Connecticut, United States
START Midwest
Grand Rapids, Michigan, United States
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
NEXT Oncology
Fairfax, Virginia, United States
Start Date
December 5, 2025
Primary Completion Date
October 30, 2028
Completion Date
October 30, 2028
Last Updated
April 1, 2026
NCT05919264
NCT07403721
NCT03093116
NCT06248411
NCT04977453
NCT06716138
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions